Quantum Cyber N.V. current report, Q1 FY2022

Business Context and Reporting Period

This Form 6-K filing covers the month of January 2022 for Mainz Biomed N.V., a foreign private issuer. The company is developing ColoAlert, a detection test for colorectal cancer (CRC). The filing reports on a material definitive agreement entered into on January 4, 2022.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a strategic business agreement rather than financial performance data.

Material Changes

On January 4, 2022, Mainz Biomed N.V. entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS"). Key terms include:

  • Access to a portfolio of novel mRNA biomarkers owned by TTS for potential integration into the ColoAlert test.
  • A unilateral option to license exclusive, global rights to five gene expression biomarkers developed at the Université de Sherbrooke.
  • The biomarkers have demonstrated a potentially high degree of effectiveness in detecting CRC lesions, including advanced adenomas.

Outlook, Risks, and Management Commentary

Management announced the agreement via a press release on January 5, 2022. The strategic outlook involves integrating these new biomarkers to enhance the detection capabilities of the ColoAlert test. The filing does not explicitly detail specific risks, contingencies, or unusual items beyond the standard nature of entering into a new licensing agreement.

Investor Verification Checklist

  • Verify the specific financial terms and payment obligations of the Technology Rights Agreement with TTS.
  • Confirm the timeline and conditions required to exercise the unilateral option for exclusive global rights.
  • Review the attached press release (Exhibit 99.1) for additional details on the biomarker portfolio.
  • Assess the regulatory pathway for integrating the new mRNA biomarkers into the existing ColoAlert test.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.